560082-51-1

Basic information

• Product Name: 8-FLUORO-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE
• Synonyms: 8-FLUORO-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE
• CAS NO: 560082-51-1
• Molecular Formula: C₈H₆FNO₂
• Molecular Weight: 167.14
• EINECS: 604-604-1
• Mol File: 560082-51-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 320.8±42.0 °C(Predicted)
• Appearance: /
• Density: 1.347±0.06 g/cm3(Predicted)
• PKA: 11.69±0.20(Predicted)
• CAS DataBase Reference: 8-FLUORO-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 8-FLUORO-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE(560082-51-1)
• EPA Substance Registry System: 8-FLUORO-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE(560082-51-1)

Safety Data

• Hazardous Substances Data: 560082-51-1(Hazardous Substances Data)

Usage

Description

8-FLUORO-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE is a fluorinated benzo[b][1,4]oxazinone derivative with the molecular formula C8H5FNO2. It is a heterocyclic compound that features a benzene ring fused to an oxazine ring, and its fluorinated structure may confer unique properties and characteristics for various applications in medicinal chemistry and drug discovery.

Uses

Used in Pharmaceutical Research and Drug Development:
8-FLUORO-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE is used as a potential building block for the synthesis of biologically active molecules. Its presence in pharmaceutical research and drug development is due to its potential to contribute to the creation of new drugs and therapies.
Used in Medicinal Chemistry:
8-FLUORO-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE is used as a component in medicinal chemistry to explore its impact on the bioavailability, metabolic stability, and other pharmacological properties of molecules. The presence of a fluorine atom in this compound can enhance these properties, making it a valuable asset in the development of effective drugs.

Upstream product

• 1526-17-6 2-fluoro-6-nitrophenol 
• 53981-25-2 2-amino-6-fluoro phenol 
• 79-04-9 chloroacetyl chloride 
• 698984-51-9 (2-fluoro-6-nitrophenoxy)acetic acid, methyl ester 

Downstream Products

• 898832-40-1 8-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxazine 
• 1350660-14-8 4-benzyl-8-fluoro-1,4-benzoxazin-3-one 
• 1350660-12-6 4-[5-(benzyloxy)pyrimidin-2yl]-8-fluoro-3,4-dihydro-2H-benzo-[1,4]oxazine 
• 1350660-15-9 4-benzyl-8-fluoro-3-methyl-2,3-dihydro-1,4-benzoxazine 
• 1350659-87-8 SEN₁₅₇₆ 
• 1350659-91-4 8-fluoro-4-[5-[3-(4-methylpiperazin-1-yl)phenoxy]pyrimidin-2-yl]-3,4-dihydro-2H-benzo[1,4]oxazine 
• 1350659-92-5 8-fluoro-4-[5-(3-morpholinophenoxy)-2-pyridyl]-3,4-dihydro-2H-benzo-[1,4]oxazine 
• 1350659-95-8 (R)-8-fluoro-4-[5-(3-(3-methylmorpholin-4-yl)phenoxy)pyrimidin-2-yl]-3,4-dihydro-2H-benzo[1,4]oxazine 
• 1350659-96-9 (S)-8-fluoro-4-[5-(3-(3-methylmorpholin-4-yl)phenoxy)pyrimidin-2-yl]-3,4-dihydro-2H-benzo[1,4]oxazine 
• 1350659-97-0 8-fluoro-4-[5-(3-methoxyphenoxy)pyrimidin-2-yl]-3,4-dihydro-2H-benzo[1,4]oxazine 
• 1350659-98-1 8-fluoro-4-[5-(3-N,N-dimethylaminophenoxy)pyrimidin-2-yl]-3,4-dihydro-2H-benzo[1,4]oxazine 
• 1350659-99-2 4-(5-(3-bromophenoxy)pyrimidine-2-yl)-8-fluoro-3,4-dihydrobenzo[1,4]oxazine 
• 1350660-00-2 1-{3-[2-(8-fluoro-2,3-dihydro-benzo[1,4]oxazin-4-yl)-pyrimidin-5-yloxy]-phenyl}azetidin-3-ol 
• 1350660-02-4 8-fluoro-3-methyl-4-[5-(3-morpholin-4-yl-phenoxy)pyrimidin-2-yl]-3,4-dihydro-2H-benzo[1,4]oxazine 

Relevant articles and documents

Tetrahydroquinoline analogues as muscarinic agonists

The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.

COMPOUNDS

A compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof wherein X is N or CH; Q is NR6 or O; A1 and A2 are independently hydrogen or C1-6 alkyl or may together form a carbonyl group; R1 and R2 are independently hydrogen, halogen, CF3, CN, OR7, OR8, NR8R9, NR8COR10, NR8S02R10, S02NR8R9, SO2R10 or C1-6 alkyl optionally and independently substituted by one or more of hydroxyl, C1-6 alkoxy, halogen or NR8 R9; R 3 is hydrogen, halogen, CF3 or OR 7; R4 is hydrogen, halogen, CF3, OR8, NR8R9, NR8COR10, NR8S02R10 or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR 8 R 9; or when R3 and R4 are positioned ortho and taken together form -0(CH2)mO-, where m is 1-3; R5 is hydrogen or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR8 R9; R6 is hydrogen or C1-6 alkyl; R7 is hydrogen or C1-6 alkyl optionally substituted by OR8 or NR8R9; R8 is hydrogen, C1-6 alkyl, optionally substituted by hydroxyl or C1-6 alkoxy or C1-3 alkylphenyl wherein said phenyl group is optionally substituted by one or more substituents selected from halogen, C1-6 alkyl, CF3, OR7, NR8R9 or OCF3; or the groups R8 and R9 when they are attached to a nitrogen atom may together form a 5- or 6-membered ring which optionally contains one further heteroatom selected from NR7, S and O said 5 or 6 membered ring being optionally substituted by hydroxyl or C1-6 alkoxy; or the groups R8 and R9 when they are attached to a nitrogen atom may together form an azetidinyl ring optionally substituted by hydroxyl or C1-6 alkoxy; and R10 is C1-6 alkyl or a phenyl group optionally substituted by one or more substituents selected from halogen, C1-6 alkyl, CF3, OCF3 or OR7; and n is 1 or 2. The use of the compounds in treating amyloid disease is also disclosed.

6-[2-(4-Aryl-1-piperazinyl)ethyl]-2H-1,4-benzoxazin-3(4H)-ones: Dual-acting 5-HT1 receptor antagonists and serotonin reuptake inhibitors

Investigation of a series 6-[2-(4-aryl-1-piperazinyl)ethyl]-2H-1,4-benzoxazin-3(4H)-ones has led to the discovery of potent 5-HT1A/1B/1D receptor antagonists with and without additional SerT affinity. Modulation of the different target activities gave compounds with a range of profiles suitable for further in vivo characterization.